# A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

> **NCT03817476** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** iCF1(T1) 25 milligram BI 425809
- **DRUG:** iCF2(T2) 25 milligram BI 425809
- **DRUG:** TF2(R) 25 milligram BI 425809

## Key facts

- **NCT ID:** NCT03817476
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-11
- **Primary completion:** 2019-05-28
- **Final completion:** 2019-05-28
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817476, "A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03817476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*